# EDGAR Filing Document

**Accession Number:** 0001861657
**File Stem:** 0001493152-26-005453
**Filing Date:** 2026-2
**Character Count:** 65762
**Document Hash:** 20b0af832db3ea97bc046091fee36c8e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-005453.hdr.sgml**: 20260206

**ACCESSION NUMBER**: 0001493152-26-005453

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260205

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260206

**DATE AS OF CHANGE**: 20260206

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tharimmune, Inc.
- **CENTRAL INDEX KEY:** 0001861657
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 842642541
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41210
- **FILM NUMBER:** 26605273

**BUSINESS ADDRESS:**
- **STREET 1:** 1200 ROUTE 22 EAST
- **CITY:** BRIDGEWATER
- **STATE:** NJ
- **ZIP:** 08807
- **BUSINESS PHONE:** 302-743-2995

**MAIL ADDRESS:**
- **STREET 1:** 34 SHREWSBURY AVE
- **STREET 2:** SUITE 1C
- **CITY:** RED BANK
- **STATE:** NJ
- **ZIP:** 07701

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Tharimmune, Inc
- **DATE OF NAME CHANGE:** 20230925

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Hillstream BioPharma Inc.
- **DATE OF NAME CHANGE:** 20210511

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **February 5, 2026**

**THARIMMUNE, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41210** | **84-2642541** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (I. R. S. Employer<br> Identification No.) |

---

**34 Shrewsbury Avenue, Suite 1C**

**Red Bank, NJ 07701**

(Address of principal executive offices, including zip code)

**(732) 889-3111**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common stock, $0.0001 par value | THAR | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** |

---

On February 5, 2026, the Board of Directors (the "**Board**") of Tharimmune, Inc. (the "**Company**") appointed Angela Dominy Radkowski, age 37, as Chief Operating Officer of the Company, effective February 5, 2026 (the "**Effective Date**").

Prior to her appointment, Ms. Radkowski served as Operations Strategy Lead and Chief of Staff to the Chief Operating Officer at DRW Holdings LLC from February 2022 to January 2026, advising senior leadership, coordinating cross-functional communication, and managing high-priority, enterprise-level initiatives. Ms. Radkowski previously held positions within Citadel LLC's Treasury and Engineering organizations, where she was responsible for coordinating enterprise deliverables involving optimization, data engineering, and technology upgrades. Ms. Radkowski holds a Bachelor of Science in Business Administration with a major in Finance from The Ohio State University, Max M. Fisher College of Business.

There are no arrangements or understandings between Ms. Radkowski and any other person pursuant to which Ms. Radkowski was appointed to serve as Chief Operating Officer of the Company. There are no family relationships between Ms. Radkowski and any of the Company's directors or executive officers. Ms. Radkowski has no direct or indirect material interest in any existing or currently proposed transaction that would require disclosure under Item 404(a) of Regulation S-K.

In connection with her appointment as Chief Operating Officer, the Company entered into an employment agreement with Ms. Radkowski setting forth the terms and conditions of her employment with the Company (the "**COO Employment Agreement**") dated February 5, 2026. Under the terms of the COO Employment Agreement, Ms. Radkowski will be entitled to receive: (i) an annual base salary of $300,000, subject to review and adjustment by the Company from time to time; and (ii) eligibility for an annual cash-based performance bonus, in an amount determined by the Board in its sole and absolute discretion, with a target amount equal to $100,000, subject to continuous employment with the Company, provided that the annual bonus for the 2026 calendar year shall be prorated based on the number of days that Ms. Radkowski is employed by the Company during such calendar year. Ms. Radkowski will also be eligible to receive grants of time-based and/or performance-based equity awards, in a form and amount determined by the Board in its sole and absolute discretion, subject to Board approval, vesting conditions established by the Board (or its compensation committee) and other conditions. The agreement contains customary confidentiality, non-compete, non-solicitation, and intellectual property provisions.

The COO Employment Agreement provides that Ms. Radkowski's employment is at will and may be terminated by either party at any time, with or without cause or notice. The COO Employment Agreement provides that in the event Ms. Radkowski terminates her employment for "good reason" (as defined in the COO Employment Agreement) or the Company terminates her employment without "cause" (as defined in the COO Employment Agreement), she is entitled to receive the following benefits, subject to her execution of a general release of claims in the Company's favor and obligations regarding solicitation, return of property, and restrictive covenants, non-solicitation of customers, non-solicitation of employees, non-disparagement and the expiration of any applicable expiration period with respect to the release: (i) any base salary earned through the date of termination; (ii) unpaid expense reimbursement in accordance with our policy; (iii) unused vacation and sick leave that accrued through the date of termination in accordance with our policy; and (iv) twelve (12) months of base salary.

In the event Ms. Radkowski voluntarily resigns other than for "good reason" (as defined in the COO Employment Agreement) or her employment is terminated by us for "cause" (as defined in the COO Employment Agreement), she will be entitled to receive: (i) any base salary earned through the date of termination; (ii) unpaid expense reimbursement in accordance with our policy; and (iii) unused vacation and sick leave that accrued through the date of termination in accordance with our policy.

The foregoing description of the COO Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the COO Employment Agreement, which is filed as Exhibit 10.1 and incorporated by reference herein.

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD Disclosures.** |

---

*Board Leadership Update*

On February 5, 2026, during a special meeting of the Board of Directors, Mark Wendland, current Director and Chief Executive Officer of the Company, was elected as the Chairman of the Board.

In addition, the Board also elected the following directors to serve on its committees:

● Audit Committee: Gary Stetz (as the Chair), Clay Kahler and Jill E. Sommers.

● Compensation Committee: Gary Stetz (as the Chair), Clay Kahler, and Jill E. Sommers.

● Nominating & Corporate Governance Committee: Gary Stetz, Clay Kahler (as the Chair), and Jill E. Sommers.

*Press Release*

On February 6, 2026 the Company issued a press release announcing the appointment of Ms. Radkowski and the change in Board leadership, a copy of which is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.** |

---

On February 2, 2025, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("**Nasdaq**") notifying that the Company had regained compliance with Nasdaq Listing Rule 5605(b)(1) (the "**Board Independence Rule**"). As previously reported, on January 9, 2026, the Company received a deficiency letter from Nasdaq indicating that it was not in compliance with the Board Independence Rule. Compliance was regained following the Company's election of two independent directors on the shareholders meeting held on January 30, 2026.

**Forward-Looking Statements**

The information set forth in this Current Report on Form 8-K ("**Current Report**"), including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "**Exchange Act**"), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibit** |
| 10.1# | [Employment Agreement with Angela Dominy Radkowski, dated February 5, 2026](ex10-1.htm) |
| 99.1 | [Press Release, dated February 6, 2026](ex99-1.htm) |
| 104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. |

---

# Indicates a management contract or any compensatory plan, contract or arrangement.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| Date: February 6, 2026 | **Tharimmune, Inc.** |
|  | */s/ Mark Wendland* |
|  | Mark Wendland |
|  | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**EMPLOYMENT AGREEMENT**

This Employment Agreement (this "Agreement") is made as of February 5, 2026 and is entered into by and between Tharimmune, Inc. (the "Company") and Angela Radkowski ("Employee") (collectively with the Company, the "Parties"; each of the Parties referred to individually as a "Party").

**WHEREAS**, the Company desires to employ Employee in accordance with the terms and conditions set forth below; and

**WHEREAS**, Employee desires to be employed by the Company in accordance with the terms and conditions set forth below.

**NOW, THEREFORE**, in consideration of the promises and mutual covenants and agreements set forth in this Agreement, the Parties hereby agree as follows:

1.  **<u>EMPLOYMENT</u>** .

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.  **<u>Title</u>** .
 The Company hereby agrees to employ Employee, and Employee hereby accepts such employment,
 as Chief Operating Officer of the Company, reporting to the Chief Executive Officer of the
 Company (the "CEO").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.  **<u>Employment Period</u>** . Employee's employment with the Company shall commence on a mutually
 agreed date (which is anticipated to be on or around February 5, 2026, the "Start Date").
 This Agreement shall be effective as of the Start Date and shall continue until terminated
 in accordance with the terms of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.  **<u>Principal Place of Employment</u>** . Employee's principal place of employment shall be Chicago,
 Illinois; provided, however, that it is understood that travel may be necessary to fulfill
 Employee's duties hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.  **<u>At Will Relationship</u>** . Employee's employment with the Company shall commence as
 of the Start Date. Employee's employment shall be considered "at will"
 in nature and, accordingly, either the Company or Employee may terminate this Agreement and
 Employee's employment at any time and for any reason, with or without cause or prior
 notice. Nothing in this Agreement, including but not limited to Section 3 hereof, shall be
 construed as, or shall interfere with, abridge, limit, modify, or amend the "at will"
 nature of Employee's employment with Company. Except as set forth in Section 3 of this
 Agreement, upon Employee's separation from employment with the Company (for any reason),
 all compensation and benefits payable or provided to Employee shall, except as required by
 applicable law, terminate as of the effective date of Employee's termination (the "Termination
 Date").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e.  **<u>Duties and Responsibilities</u>** . During Employee's employment with the Company, Employee
 shall at all times: (i) comply with the terms and conditions set forth in this Agreement;
 (ii) perform and carry out such responsibilities, duties, and authorities as the Company
 may direct, designate, request of, or assign to Employee from time to time, which shall include,
 but not necessarily be limited to, such duties, responsibilities and authorities that are
 typically performed by and assigned to employees in similar positions within similar companies;
 (iii) perform the duties and carry out the responsibilities assigned to her by the Company
 to the best of her ability, in a trustworthy, business-like, and efficient manner for the
 purpose of advancing the business and interests of the Company; (iv) devote sufficient time,
 attention, effort, and skill to her position with and the business of the Company; (v) comply
 with and abide by the Company's policies, practices, and procedures (as may be amended
 or otherwise modified from time to time by the Company); and (vi) comply with all laws, rules,
 regulations, and licensing requirements of, or that may be applicable to, her employment
 with the Company.

In the event that any term(s) of this Agreement conflicts with a term(s) of any employee handbook, policy, practice, or procedure adopted or maintained, at any time, by the Company, the term(s) of this Agreement shall control and supersede such conflicting term(s).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f.  **<u>No Conflicts</u>** . Employee represents and warrants that she is not bound by or subject to
 any written or oral agreement, pact, covenant, or understanding with any previous or concurrent
 employer, or any other party, that would limit, abridge, restrict, or interfere with, in
 any way, her ability to perform her duties and obligations hereunder. Employee further represents
 and warrants that the performance of her duties and obligations hereunder shall not violate
 any written or oral agreement, pact, covenant, or understanding by and between her and any
 previous or concurrent employer, or any other party. Employee further represents and warrants
 that she will not use any trade secret, or confidential or proprietary information, of any
 of her previous or concurrent employers, or that was obtained, learned, or procured during
 any period of employment prior to or concurrent with her employment with the Company, in
 connection with her employment with the Company or in the performance of her duties and obligations
 hereunder.

2.  **<u>COMPENSATION AND BENEFITS</u>** <u>.</u> Subject to the terms and conditions of Sections 1 and 3 of this
 Agreement and Employee's continued employment with the Company, and in consideration
 for the services to be provided hereunder by Employee, the Company hereby agrees to pay or
 otherwise provide Employee with the following compensation and benefits during her employment
 with the Company:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.  **<u>Annual Salary</u>** . The Company shall pay Employee a base salary equal to $300,000 per year (as
 it may be adjusted from time to time, the "Annual Salary"), less applicable taxes,
 withholdings, and deductions, and any other deductions that may be authorized by Employee,
 from time to time, in accordance with applicable federal, state, and/or local law. The Annual
 Salary shall be payable in accordance with the Company's standard payroll practices
 and procedures, as in effect from time to time. Employee acknowledges and understands that
 her position of employment with the Company is considered "exempt," as that term
 is defined under the Fair Labor Standards Act and applicable state or local law. As an exempt
 employee, Employee is not eligible to receive overtime pay.

Notwithstanding the foregoing, the Annual Salary may be reviewed by the Company from time to time and may be subject to upward or downward adjustment, in the Company's sole discretion, based upon a review and consideration of various factors, including but not limited to Employee's performance and/or the Company's overall financial performance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.  **<u>Bonus</u>** .
 Subject to the conditions set forth herein, Employee will be eligible for an annual performance-based
 cash bonus in an amount determined by the board of directors of the Company (the "Board")
 in its sole and absolute discretion (the "Annual Bonus"). The target level for
 the Annual Bonus is equal to $100,000. The Annual Bonus will be payable in the form of a
 lump sum cash payment no later than March 15th of the calendar year that immediately follows
 the calendar year to which the Annual Bonus relates. In order for Employee to be eligible
 to receive the Annual Bonus pursuant to this Section 2(b), Employee must remain continuously
 employed by the Company through the payment date to which such Annual Bonus relates. Notwithstanding
 the foregoing, for the period between the Start Date and December 31, 2026, the Annual Bonus
 shall be prorated based on the number of days that the Employee is employed by the Company
 during such calendar year, beginning on the Start Date, divided by the total number of days
 in such calendar year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.  **<u>Equity Awards</u>** . At a time determined by the Board, Employee will be eligible to receive grants
 of time-based and/or performance-based equity awards under the Tharimmune, Inc. 2023 Omnibus
 Equity Incentive Plan, as amended (the "Plan") in a form and amount determined
 by the Board, in its sole and absolute discretion (the "Equity Awards"). The
 Equity Awards shall be subject (i) approval of the Board, (ii) timely execution of an award
 agreement (the "Award Agreement"), (iii) the terms and conditions of the Award
 Agreement and the Plan, and (iv) time-vesting and/or performance-vesting metrics established
 by the Board (or its compensation committee), in consultation with the Chief Executive Officer,
 which metrics and/or vesting conditions may vary from year to year.

Each Equity Award shall be subject to Employe's continued employment with the Company and good standing through each applicable vesting date and to other customary terms to be set forth in the corresponding Award Agreement and the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.  **<u>Benefit Plans</u>** . Employee shall be entitled to participate in any and all medical insurance,
 group health, disability insurance, life insurance, incentive, savings, retirement, and other
 benefit plans, if any, which are made generally available to similarly-situated employees
 of the Company (and subject to eligibility requirements, enrollment criteria, and other terms
 and conditions of such plans), and which the Company (or any affiliate maintaining any such
 arrangement), in its sole discretion, may at any time amend, modify, or terminate, subject
 to the terms and conditions of such plans and applicable federal, state, or local law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e.  **<u>Vacation and Sick Leave</u>** . Employee shall be entitled to vacation and sick leave in accordance
 with the Company's respective vacation and sick leave policies, as in effect from time
 to time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f.  **<u>Expenses</u>** .
 Employee shall be entitled to reimbursement for all reasonable expenses that she incurs in
 connection with the performance of her duties and obligations hereunder. Upon presentment
 by Employee of appropriate and sufficient documentation, as determined in the Company's
 sole discretion, the Company shall reimburse Employee for all such expenses in accordance
 with the Company's expense reimbursement policy, as in effect from time to time.

3. **<u>EFFECT OF TERMINATION</u>**. Employee's employment may be terminated by the Company for Cause (as defined below) or without Cause or by Employee's resignation for any reason. In the event of any such termination, Employee shall only be entitled to the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. <u>Termination of Employment for Any Reason, Resignation by the Employee without Good Reason, or Termination by the Company for Cause</u>. If Employee's employment is terminated for any reason,
 is terminated by the Company for Cause or Employee resigns from her employment for any reason
 other than Good Reason (as defined below), then in full satisfaction of the Company's
 obligations under this Agreement, Employee shall be entitled to receive (i) any vacation
 accrued but unused as of the Termination Date, subject to the Company's policies regarding
 vacation pay, and (ii) any Annual Salary earned but unpaid as of the Termination Date (the
 "Accrued Obligations").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. <u>Termination by the Company without Cause, or Resignation by the Employee for Good Reason</u>. If Employee's
 employment is terminated by the Company without Cause or by Employee for Good Reason (as
 defined below), subject to Employee executing and not revoking a general release of all claims
 against the Company, its subsidiaries, and any of their respective affiliates in a form to
 be provided to Employee from the Company (a "Release") and the expiration of
 any applicable revocation period with respect to the Release within forty-five (45) days
 after Employee's Termination Date (the last day of the maximum period of time that
 the Release can be executed and no longer revocable, the "Release Consideration Expiration
 Date", and the actual date in which the Release is fully effective and no longer revocable,
 the "Release Effective Date"), then in full satisfaction of the Company's
 obligations under this Agreement, Employee shall be entitled to receive the following: (i)
 an amount equal to twelve (12) months of then-current Annual Salary, as of the Termination
 Date, which shall be paid, in equal monthly installments in accordance with the Company's
 general payroll practices, with the first installment to be paid on the first payroll date
 following the effective date of the Release (the "Severance Payment Commencement Date"),
 with any such payments that would have otherwise been made to Employee following their Termination
 Date but prior to the Release Effective Date to be paid on the Severance Payment Commencement
 Date; and (ii) any Accrued Obligations as of the Termination Date.

For purposes herein, "Cause" shall mean the occurrence of any one or more of the following events, as determined in the sole discretion of the Company:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Employee's
 willful misconduct, gross negligence, or material failure to perform the duties and responsibilities
 of her position (other than as a result of physical or mental incapacity), after written
 notice from the Company and a reasonable opportunity to cure, if curable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Employee's
 material violation of any written policy, code of conduct, or procedure of the Company, its
 subsidiaries, or any of their respective affiliates, including but not limited to those relating
 to harassment (including sexual harassment), discrimination, workplace safety, or substance
 abuse.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Employee's
 commission of any conduct which causes or could reasonably be expected to cause material
 financial or reputational harm to the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Employee's
 commission of, or participation in, any act of fraud, dishonesty, embezzlement, misappropriation,
 or other act of material misconduct with respect to the Company, its subsidiaries, or any
 of their respective affiliates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. Employee's
 commission of, indictment for, conviction of, or plea of guilty or nolo contendere to, a
 felony or any crime involving moral turpitude, dishonesty, or theft.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. Employee's
 material breach of this Agreement or any other written agreement with the Company, its subsidiaries,
 or any of their respective affiliates, or Employee's breach of any fiduciary duty owed
 to the Company, its subsidiaries, or any of their respective affiliates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;g. Employee's
 unauthorized use or disclosure of any confidential or proprietary information of the Company,
 its subsidiaries, or any of their respective affiliates, or breach of any non-solicit, confidentiality,
 or other restrictive covenant to which the Employee may be subject, including, without limitation,
 Section 4 of this Agreement.

"Good Reason" shall mean Employee's termination of her employment in accordance with the next sentence after the occurrence of one or more of the following events without Employee's express written consent: (i) a material diminishment of Employee's job title; (ii) a material reduction by the Company in Employee's rate of Annual Salary (other than diminutions of annual salaries across the board for senior executives and not exceeding 20%); (iii) the Company's material breach of this Agreement, after written notice from Employee and a reasonable opportunity to cure; or (iv) Employee being required to relocate the Employee's primary work location to a facility or location that would increase the Employee's one way commute distance by more than thirty (30) miles from the Employee's primary work location as of immediately prior to such change; provided, that a relocation of less than thirty (30) miles from Employee's then present location will not be considered a material change in geographic location.

4. **<u>RESTRICTIVE COVENANTS</u>**. The Parties agree that the Company, its subsidiaries and their respective affiliates are engaged in a highly competitive industry and would suffer irreparable harm and incur substantial damage if Employee were to enter into competition with the Company and its subsidiaries and affiliates. Therefore, in order for the Company to protect its legitimate business interests, Employee covenants and agrees as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Employee
 shall not, at any time during her employment with the Company and for a period of twelve
 (12) months thereafter, anywhere in the world or any jurisdiction in which the Company and
 its subsidiaries and affiliates conduct material business operations (the "Restricted
 Territory), either directly or indirectly: (i) accept employment with or render services
 to (whether as an agent, servant, owner, partner, consultant, employee, independent contractor,
 representative, director, officer, or stockholder) any person or entity that is a business
 competitor of the Company and its subsidiaries and affiliates or entity that competes with
 the Company and its subsidiaries and affiliates in the field of digital asset treasury ("DAT")

 or has at any time during Employee's employment with the Company engaged or attempted
 to engage in business competition with the Company and its subsidiaries and affiliates, in
 a position, capacity, or function that is similar, in title or substance, whether in whole
 or in part, to any position, capacity, or function that Employee held with or in which Employee
 served the Company; or (ii) invest in any person or entity that is a business competitor
 of the Company and its subsidiaries and affiliates, or has at any time during Employee's
 employment with the Company engaged or attempted to engage in business competition with the
 Company and its subsidiaries and affiliates, except that Employee may own up to one percent
 (1%) of any outstanding class of securities of any company registered under Section 12 of
 the Securities Exchange Act of 1934, as amended;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Employee
 shall not, at any time during her employment with the Company and for a period of twenty-four
 (24) months thereafter (the "Restricted Period") in the Restricted Territory,
 for any reason, on her own behalf or on behalf of any other person or entity, by or through
 any means including but not limited to social media: (i) solicit, invite, induce, cause,
 or encourage to alter or terminate his, her, or its business relationship with the Company
 and its subsidiaries and affiliates, any client, customer, supplier, vendor, licensee, licensor,
 or other person or entity that, at any time during Employee's employment with the Company,
 had a business relationship with the Company and its subsidiaries and affiliates, or any
 person or entity whose business the Company and its subsidiaries and affiliates was soliciting
 or attempting to solicit at the time of Employee's termination, (a) for whom Employee
 performed services or with whom Employee had contact during her employment with the Company,
 or whose business Employee was soliciting or attempting to solicit at the time of Employee's
 termination, and (b) with whom Employee did not have a business relationship prior to her
 employment with the Company; (ii) solicit, entice, attempt to solicit or entice, or accept
 business from any such client, customer, supplier, vendor, licensee, licensor, person, or
 entity; or (iii) interfere or attempt to interfere with any aspect of the business relationship
 between the Company and its subsidiaries and affiliates and any such client, customer, supplier,
 vendor, licensee, licensor, person, or entity; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Employee
 shall not, at any time during the Restricted Period in the Restricted Territory, either directly
 or indirectly, on her own behalf or on behalf of any other person or entity, by or through
 any means including but not limited to social media: (i) solicit, invite, induce, cause,
 or encourage any director, officer, employee, agent, representative, consultant, or contractor
 of the Company and its subsidiaries and affiliates to alter or terminate his, her, or its
 employment, relationship, or affiliation with the Company and its subsidiaries and affiliates;
 (ii) interfere or attempt to interfere with any aspect of the relationship between the Company
 and its subsidiaries and affiliates and any such director, officer, employee, agent, representative,
 consultant, or contractor; or (iii) engage, hire, or employ, or cause to be engaged, hired,
 or employed, in any capacity whatsoever, any such director, officer, employee, agent, representative,
 consultant, or contractor.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Employee
 covenants and agrees that Employee shall not make any statement, written or verbal, in any
 forum or media, or take any other action or engage in any conduct that disparages the Company
 and its subsidiaries and affiliates, their services, products, officers, directors, managers,
 employees, shareholders, members, investments or agents. The Company and its subsidiaries
 and affiliates covenant and agree that the Company and its subsidiaries and affiliates shall
 not make any statement, written or verbal, in any forum or media, or take any other action
 or engage in any conduct that disparages Employee. Nothing in this Section 4(d) shall prohibit
 any Person from (A) testifying truthfully in any legal or administrative proceeding or otherwise
 truthfully responding to any other request for information or testimony to which such Person
 is legally required to respond; (B) making any truthful statement to the extent necessary
 to rebut any untrue public statements made by another Person; (C) making any statement or
 engaging in any conduct that would constitute a permitted disclosure; (D) making any truthful
 statement as part of or in any arbitration or court proceeding that involves such Person;
 or (E) making any truthful statement or expression of opinion in connection with requests
 from third parties for employment references or in connection with discussions involving
 matters of workplace concern, such as performance review, bonus determination, or investigation.

Employee represents, warrants, agrees, and understands that: (i) the covenants and agreements set forth in this Section 4 of the Agreement are reasonable in their geographic scope, temporal duration, and the type and scope of activities they restrict; (ii) the Company's agreement to employ Employee, and a portion of the compensation to be paid to Employee hereunder, are in consideration for such covenants and Employee's continued compliance therewith, and constitute adequate and sufficient consideration for such covenants; (iii) Employee shall not raise any issue of, nor contest or dispute, the reasonableness of the geographic scope, temporal duration, or content of such covenants and agreements in any proceeding to enforce such covenants and agreements; (iv) the enforcement of any remedy under this Agreement will not prevent Employee from earning a livelihood, because Employee's past work history and abilities are such that Employee can reasonably expect to find work in other areas and lines of business; (v) the covenants and agreements set forth in this Section 4 of the Agreement are essential for the Company's and its subsidiaries and affiliates reasonable protection, are designed to protect the Company's and its subsidiaries and affiliates legitimate business interests, and are necessary and implemented for legitimate business reasons; and (vi) in entering into this Agreement, the Company has relied upon Employee's representation that she will comply in full with the covenants and agreements set forth in this Section 4 of the Agreement.

If Employee breaches Section 4(a), 4(b), or 4(c) above, then the period during which that section remains in effect shall be extended by the length of time during which such breach continues.

5. **<u>CONFIDENTIALITY</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.  **<u>Confidential Information</u>** . Employee acknowledges that during her employment with the Company, and
 by the nature of Employee's duties and obligations hereunder, Employee will come into
 close contact with confidential information of the Company and its subsidiaries, affiliates,
 and/or other related entities, as applicable, including but not limited to: trade secrets,
 know-how, Intellectual Property (as that term is defined below), business plans, client/customer
 lists, pricing, sales and marketing information, products, research, algorithms, market intelligence,
 services, technologies, concepts, methods, sources, methods of doing business, patterns,
 processes, compounds, formulae, programs, devices, tools, compilations of information, development,
 manufacturing, purchasing, engineering, computer programs (whether in source code or object
 code), theories, techniques, procedures, strategies, systems, designs, works of art, the
 identity of and any information concerning affiliates or customers, or potential customers,
 information received from others that the Company and its subsidiaries and affiliates are
 obligated to treat as confidential or proprietary, and any other technical, operating, non-public
 financial, and other business information that has commercial value, whether relating to
 the Company, its business, potential business, or operations, or the business of any of the
 Company's and its affiliates, subsidiaries, related entities, clients, customers, suppliers,
 vendors, licensees, or licensors, that Employee may develop or of which Employee may acquire
 knowledge during her employment with the Company, or from her colleagues while working for
 the Company, whether prior to, during, or subsequent to her execution of this Agreement,
 and all other business affairs, methods, and information not readily available to the public
 (collectively, "Confidential Information"). Confidential Information does not
 include: (i) Employee's general skills and experience; (ii) information that was lawfully
 in Employee's possession prior to her employment with the Company (other than through
 breach by a third party of any confidentiality obligation to the and its subsidiaries and
 affiliates); (iii) information that is or becomes publicly available without any direct or
 indirect act or omission on Employee's part; (iv) information that is required to be
 disclosed pursuant to any applicable law, regulation, judicial or administrative order or
 decree, or request by other regulatory organization having authority pursuant to the law;
 provided, however, that, except as set forth in and subject to Section 5(b) of this Agreement,
 Employee shall first have given reasonable notice to the Company prior to making such disclosure;
 or (v) information that is generally known within the industries or trades in which the Company
 and its subsidiaries and affiliates transact business.

The term "Intellectual Property" means all discoveries, procedures, designs, creations, developments, improvements, methods, techniques, practices, methodologies, data models, databases, scripts, know-how, processes, algorithms, application program interfaces, software programs, software source documents and training manuals, codes, formulae, works of authorship, mask-works, reports, memoranda, ideas, inventions, customer lists, business and/or financial information, and contributions of any kind, whether or not they are patentable, registrable, or protectable under federal or state patent, copyright, or trade secret laws, or similar statutes, or protectable under common-law principles, and regardless of their form or state of development, that are made, conceived, generated, or reduced to practice by Employee, in whole or in part, either alone or jointly with others, or while Employee was serving as an officer, director, employee, or consultant of, or in any other capacity with, the Company. Notwithstanding anything else in this Agreement, and as it used in this Section 5, the term "Intellectual Property" excludes any software program, application program interface, equipment, supplies, resources, facilities, data, products, information, materials, or trade secrets used by the Company and its subsidiaries and affiliates, and which was developed entirely on Employee's own time, unless said Intellectual Property: (i) relates to the Company's and its subsidiaries and affiliates business or potential business; or (ii) results from tasks assigned to Employee by the Company or from work performed by Employee for the Company.

Employee acknowledges and agrees that each and every part of the Company's and its subsidiaries and affiliates Confidential Information: (a) has been developed by the Company and its subsidiaries and affiliates at significant effort and expense; (b) is sufficiently secret to derive economic value from not being generally known to other parties; (c) is proprietary to and a trade secret of the Company and its subsidiaries and affiliates and, as such, is a valuable, special, and unique asset of the Company and its subsidiaries and affiliates; and (d) constitutes a protectable business interest of the Company and its subsidiaries and affiliates. Employee further acknowledges and agrees that any unauthorized use or disclosure of any Confidential Information by Employee will cause irreparable harm and loss to the Company and its subsidiaries and affiliates. Employee acknowledges and agrees that the Company and its subsidiaries and affiliates own the Confidential Information. Employee agrees not to dispute, contest, or deny any such ownership rights either during or after Employee's employment with the Company.

In recognition of the foregoing, and except as set forth in and subject to Section 5(b) of this Agreement, Employee covenants and agrees as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. Employee
 will use Confidential Information only in the performance of her duties and obligations hereunder
 for the Company. Employee will not use Confidential Information, directly or indirectly,
 at any time during or after her employment with the Company, for her personal benefit, for
 the benefit of any other person or entity, or in any manner adverse to the interests of the
 Company and its subsidiaries and affiliates. Further, Employee will keep secret all Confidential
 Information and will not make use of, divulge, or otherwise disclose Confidential Information,
 directly or indirectly, to anyone outside of the Company, except with the Company's
 prior written consent;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. Employee
 will take all necessary and reasonable steps to protect Confidential Information from being
 disclosed to anyone within the Company who does not have a need to know the information and
 to anyone outside of the Company, except with the Company's prior written consent;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. Employee
 shall not at any time remove, copy, download, or transmit any information from the Company
 and its subsidiaries and affiliates during the term of this Agreement, except for the benefit
 of the Company and in accordance with this Agreement and the Company's policies; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iv. Promptly
 upon Employee's termination, and in any event no later than three (3) business days
 after Employee's employment with the Company ceases, Employee shall return to the Company
 and its subsidiaries and affiliates any and all Confidential Information in her possession,
 custody, or control, including but not limited to all memoranda, notes, records, plans, reports,
 forecast, marketing information, financial records and information, employee or contractor
 records and files, client lists, training materials, trade secrets, and all other documents
 (and all copies thereof), whether in electronic or hard copy form, which Employee obtained
 while employed by the Company or otherwise serving or acting on behalf of the Company, or
 which Employee may then possess or have under Employee's control.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.  **<u>Duration of Covenant</u>** . Employee acknowledges and agrees that her obligations under this Section
 5 of the Agreement shall remain in effect forever.

Notwithstanding the foregoing, nothing in this Agreement shall be construed as, or shall interfere with, abridge, limit, restrain, or restrict Employee's (or her attorney's) right, without prior authorization from or notification to the Company: (i) to engage in any activity or conduct or any provision of the National Labor Relations Act (and, in fact, this Section 5 of the Agreement shall not apply to, among other things, any discussion of company wages, hours, and working conditions as protected by the National Labor Relations Act and/or any other applicable federal, state, or local law); (ii) to communicate with any federal, state, or local government agency charged with the enforcement and/or investigation of claims of discrimination, harassment, retaliation, improper wage payments, or any other unlawful employment practices under federal, state, or local law, or to file a charge, claim, or complaint with, or participate in or cooperate with any investigation or proceeding conducted by, any such agency; (iii) to report possible violations of federal, state, or local law or regulation to any government agency or entity, including but not limited, to the extent applicable, to the U.S. Department of Labor, the Department of Justice, the Securities and Exchange Commission (the "SEC"), the Congress, and/or any agency Inspector General, or make other disclosures that are protected under the whistleblower provisions of federal, state, or local law or regulation; or (iv) to communicate directly with, respond to any inquiry from, or provide testimony before, to the extent applicable, the SEC, the Financial Industry Regulatory Authority, any other self-regulatory organization, or any other federal, state, or local regulatory authority, regarding this Agreement or its underlying facts or circumstances.

In addition, Employee shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (A) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Further, in the event that Employee files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Employee may disclose the trade secret to her attorney and use the trade secret information in the court proceeding, if Employee: (A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.

To the extent that this Agreement conflicts with the federal Speak Out Act (Public Law No: 117-224), said act shall control and supersede the conflicting portion of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.  **<u>Retention of All Other Rights</u>** . Employee's obligations under this Section 5 of the Agreement
 are in addition to, and not in place or lieu of, any other statutory or common law obligations
 that Employee may have with regard to the maintenance, preservation, protection, use, and/or
 disclosure of Confidential Information, and the Company specifically reserves all rights
 it may have against Employee should Employee violate any such statutory or common law obligations.

6. **<u>INJUNCTIVE RELIEF</u>**. Employee agrees that it would be difficult to measure any damages caused to the Company and its subsidiaries and affiliates which might result from any breach by Employee of the covenants and agreements set forth in Sections 4 and 5 of this Agreement, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, and notwithstanding any other provision of this Agreement, Employee agrees that if Employee breaches, or the Company and its subsidiaries and affiliates reasonably believe that Employee is likely to breach, Sections 4 or 5 of this Agreement, the Company and its subsidiaries and affiliates shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach, without showing or proving any actual damage to the Company and its subsidiaries and affiliates. Any award or relief to the Company and its subsidiaries and affiliates may, in the discretion of the court, include the Company's and its subsidiaries and affiliates costs and expenses of enforcement (including reasonable attorneys' fees, court costs, and expenses). Nothing contained in this Section 6 of the Agreement or in any other provision of the Agreement shall restrict or limit in any manner the Company's and its subsidiaries and affiliates right to seek and obtain any form of relief, legal or equitable, and shall not waive the Company's and its subsidiaries and affiliates right to any other relief related to any dispute arising out of this Agreement or related to Employee's employment with the Company.

7. **<u>NOTICES</u>**. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be deemed to have been given (i) when delivered personally or by hand (with written confirmation of receipt); (ii) if sent by a nationally-recognized overnight courier, on the date received by the addressee (with written confirmation of receipt); or (iii) on the date sent by electronic mail or facsimile (with confirmation of transmission), to the recipient(s) specified below (or to such other recipient and/or address as either Party may, from time to time, designate in writing in accordance with the terms and conditions of this Agreement).

8. **<u>LEGAL REPRESENTATION</u>**. Employee acknowledges that she was advised to consult with, and has had ample opportunity to receive the advice of, independent legal counsel before executing this Agreement – and the Company hereby advises Employee to do so – and that Employee has fully exercised that opportunity to the extent she desired. Employee acknowledges that she was provided a copy of this Agreement at least fourteen (14) calendar days before the date on which the Employee was required to sign. Employee understands that she is not required to wait the full fourteen (14) days and may voluntarily choose to sign this Agreement before the end of the fourteen (14) day review period. Employee warrants that she has carefully read this Agreement, that she understands completely its contents, that she understands the significance, nature, effect, and consequences of signing it, and that she has agreed to and signed this Agreement knowingly and voluntarily of her own free will, act, and deed, and for full and sufficient consideration.

9. **<u>ENTIRE AGREEMENT; AMENDMENT</u>**. This Agreement constitutes the entire agreement between the Parties relating to the subject matter hereof, and supersedes all prior agreements and understandings, whether oral or written, with respect to the same. In entering into and performing under this Agreement, neither the Company nor Employee has relied upon any promises, representations, or statements except as expressly set forth herein. No modification, alteration, amendment, revision of, or supplement to this Agreement shall be valid or effective unless the same is memorialized in a writing signed by both by Employee and a duly-authorized representative or agent of the Company. Neither e-mail correspondence, text messages, nor any other electronic communications constitutes a writing for purposes of this Section 9 of the Agreement.

10. **<u>GOVERNING LAW</u>**. This Agreement shall in all respects be interpreted, enforced, and governed by and in accordance with the internal substantive laws (and not the laws of choice or conflict of laws) of the State of Illinois.

11. **<u>ASSIGNMENT</u>**. This Agreement shall not be assignable by Employee, but shall be binding upon Employee and upon her heirs, administrators, representatives, executors, and successors. This Agreement shall be freely assignable by the Company without restriction and, without limitation of the foregoing, shall be deemed automatically assigned by the Company with Employee's consent in the event of any sale, merger, share exchange, consolidation, or other business reorganization. This Agreement shall inure to the benefit of the Company and its successors and assigns.

12. **<u>SEVERABILITY</u>**. If one or more of the provisions of this Agreement is deemed void by law, then the remaining provisions shall continue with full force and effect and, if legally permitted, such offending provision or provisions shall be replaced with an enforceable provision or enforceable provisions that as nearly as possible effects the Parties' intent. Without limiting the generality of the foregoing, the Parties hereby expressly state their intent that, to the extent any provision of this Agreement is deemed unenforceable due to the scope, whether geographic, temporal, or otherwise, being deemed excessive, unreasonable, and/or overbroad, the court, person, or entity rendering such opinion regarding the scope shall modify such provision(s), or shall direct or permit the Parties to modify such provision(s), to the minimum extent necessary to cause such provision(s) to be enforceable.

13. **<u>SURVIVAL</u>**. Upon the termination or expiration of this Agreement, the entire Agreement shall survive such termination or expiration, and shall continue, with full force and effect, in accordance with their respective terms and conditions.

14. **<u>WAIVER</u>**. The failure of either Party to insist, in any one or more instances, upon the performance of any of the terms, covenants, or conditions of this Agreement or to exercise any right hereunder, shall not be construed as a waiver or relinquishment of the future performance of any rights, and the obligations of the Party with respect to such future performance shall continue with full force and effect. No waiver of any such right will have effect unless given in a writing signed by the Party against whom the waiver is to be enforced.

15. **<u>COMPLIANCE WITH SECTION 409A OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. It
 is the intention of the Parties that all payments and benefits under this Agreement (and
 any amendment hereto) shall be made and provided in a manner that is either exempt from or
 compliant with Section 409A of the Internal Revenue Code and the rules, regulations and notices
 thereunder ("Code Section 409A"). Any ambiguity in this Agreement (or any amendment
 hereto) shall be interpreted to comply with the above. Employee acknowledges that the Company
 has made no representations and makes no guarantee as to the treatment of the compensation
 and benefits provided hereunder and Employee has been advised to obtain her own tax advice,
 and further, Employees agrees that the Company and the Company's officers, employees,
 agents, equity holders, successors, affiliates and representatives shall have no liability
 for any of the payments or benefits under this Agreement or any other arrangement failing
 to be exempt from or to comply with Code Section 409A. Each amount or benefit payable pursuant
 to this Agreement (and any amendment hereto) shall be a separate payment for purposes of
 Code Section 409A. For all purposes of this Agreement, any iteration of the word "termination"
 (e.g., "terminated") with respect to Employee's employment shall mean a
 separation from service within the meaning of Code Section 409A. Without limiting the generality
 of the foregoing, for purposes of this Agreement, Employee shall be considered to have a
 termination of employment only if such termination is a "separation from service"
 within the meaning of Code Section 409A. If a Release Consideration Expiration Date could
 occur in a subsequent tax year, none of the payments set forth in Section 3(b) herein shall
 commence earlier than the second taxable year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. To
 the extent that the reimbursement of any benefits or the provision of any in-kind kind benefits
 pursuant to this Agreement is subject to Code Section 409A: (a) the amount of such expenses
 eligible for reimbursement, or in-kind benefits to be provided hereunder during any calendar
 year shall not affect the amount of such expenses eligible for reimbursement or in-kind benefits
 to be provided hereunder in any other calendar year; (b) all such expenses eligible for reimbursement
 hereunder shall be paid to the Employee no later than December 31<sup>st</sup> of the calendar
 year following the calendar year in which such expenses were incurred; and (c) Employee's
 right to receive any such reimbursements or in-kind benefits shall not be subject to liquidation
 or exchange for any other benefits.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Notwithstanding
 anything in this Agreement to the contrary, in the event the stock of the Company (or its
 successor) is publicly traded on an established securities market or otherwise and the Employee
 is a "specified employee" (as determined under the Company's administrative
 procedure for such determinations, in accordance with Code Section 409A) at the time of Employee's
 termination of employment, any payments under this Agreement that are deemed to be deferred
 compensation subject to Code Section 409A and payable in connection with a separation from
 service shall not be paid or begin payment until the earlier of (a) Employee's death
 or (b) the first day following the six (6) month anniversary of the Termination Date. If
 the payment of any amounts under this Agreement are delayed as a result of the previous sentence,
 on the first day following the end of the six (6) month period, the Company shall pay Employee
 a lump sum amount equal to the cumulative amounts that would have otherwise been previously
 paid to Employee under this Agreement during such six (6) month period, without interest
 thereon. To the extent permitted under Code Section 409A, any separate payment or benefits
 under this Agreement or otherwise shall not be "deferred compensation" subject
 to Code Section 409A and the six-month delay provided in this subsection, to the extent provided
 in the exceptions in Treasury Regulation Section 1.409A-1(b)(4) and (b)(9) and any other
 applicable exception or provision under Code Section 409A.

16. **<u>TAXES</u>**. The Parties acknowledge and agree that the Company may withhold from any amounts payable under this Agreement such federal, state, local, and foreign taxes and withholdings as may be required to be withheld pursuant to any applicable law, rule, or regulation.

17. **<u>SECTION HEADINGS</u>**. The section headings used in this Agreement are included solely for convenience, and shall not affect, or be used in connection with, the interpretation of this Agreement. Any reference to any gender in this Agreement shall include, where appropriate, any other gender.

18. **<u>COUNTERPARTS</u>**. This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original copy of this Agreement and all of which, when taken together, will be deemed to constitute one and the same agreement.

*(Signature Page Follows)*

 

 

**IN WITNESS WHEREOF**, the Parties have executed this Agreement as of the day and year first above written.

---

| | | | |
|:---|:---|:---|:---|
| **EMPLOYEE** | **EMPLOYEE** | **tharimmune, inc.** | **tharimmune, inc.** |
| By: | */s/ Angela Radkowski* | By: | */s/ Mark Wendland* |
|  | Angela Radkowski |  | Mark Wendland |

---

## Exhibit 99.1

**Exhibit 99.1**

**Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer** 

 

*Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy*

 

*Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion*

 

NEW YORK, February 6, 2026 — Tharimmune, Inc. (NASDAQ: THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Executive Officer, as Chairman of the Board and approved the appointment of Angela Radkowski as Chief Operating Officer, effective February 5, 2026. Mr. Wendland succeeds Vincent LoPriore, who will transition to a member of the Board after serving as Chairman since May 9, 2025.

In her role as COO, Ms. Radkowski will oversee operational control functions and enterprise processes, including the implementation of Tharimmune's Canton Network quarterly research initiative and Super Validator activation.

"I am honored to assume the role of Chairman as we continue executing on our Canton Network-aligned digital asset strategy to help modernize financial market infrastructure," said Mark Wendland. "The Board, under the dedicated leadership of Vincent LoPriore, has demonstrated an unwavering commitment to building a governance and operating structure capable of supporting our digital asset treasury strategy, and Angela's appointment adds critical leadership at a pivotal moment. Her experience scaling complex financial systems will be instrumental as we advance institutional adoption of Canton Network and drive value for shareholders."

Prior to her appointment, Ms. Radkowski served as Operations Strategy Lead and Chief of Staff to the Chief Operating Officer at DRW Holdings LLC, advising senior leadership, coordinating cross-functional communication, and managing high-priority, enterprise-level initiatives. Ms. Radkowski previously held positions within Citadel LLC's Treasury and Engineering organizations, where she was responsible for coordinating enterprise deliverables involving optimization, data engineering, and technology upgrades.

Ms. Radkowski added, "The Canton Network introduces a new model for institutional finance — one that addresses the limitations of legacy infrastructure while enabling secure, scalable blockchain adoption. I am excited to join Tharimmune and help build the operational foundation required to support this transformation."

Tharimmune established its differentiated digital asset treasury strategy in November 2025. In addition to driving value through CC acquisition and operating as a Super Validator, Tharimmune intends to invest in applications built on the Canton Network that accelerate institutional utility and adoption across capital markets. Tharimmune is the first and only publicly traded company supported by the Canton Foundation.

**About Tharimmune**

Tharimmune, Inc. (NASDAQ: THAR) is the first publicly traded company to leverage Canton Coin and support the Canton Network to advance institutional blockchain adoption and the digitization of financial markets. In addition to driving value through activities on the Canton Network, Tharimmune also operates clinical-stage biotech research and development. For more information, visit: <u>www.tharimmune.com</u>.

**Cautionary Note Regarding Forward-Looking Statements**

This press release contains statements that constitute "forward-looking statements" within the meaning of U.S. federal securities laws. Forward-looking statements are statements other than historical facts and include, without limitation, those regarding management expectations, strategy execution, market conditions, and the Company's involvement with the Canton Network. These statements are based on current expectations and involve risks and uncertainties that may cause actual results to differ materially. Further information regarding factors that may affect the Company's prospects is included in its annual and quarterly reports filed with the U.S. Securities and Exchange Commission, available at <u>www.sec.gov</u>. The Company undertakes no obligation to update these statements except as required by law.

**Contacts**

Media:

Gasthalter & Co.

(212) 257-4170

canton@gasthalter.com

Investors:

ir@tharimmune.com

**X:** @TharimmuneInc

**LinkedIn:** <u>https://www.linkedin.com/company/tharimmune-inc/</u>

**Website:** https://tharimmune.com/

# # #